跳至主要内容
临床试验/NCT00801398
NCT00801398已完成3 期

An Open-Label, Ascending, Two-Part, Single- and Multiple-Dose Evaluation of the Safety, Pharmacokinetics, and Effectiveness of Oxymorphone for Acute Postoperatiave Pain in Pediatric Subjects

Endo Pharmaceuticals11 个研究点 分布在 1 个国家目标入组 58 人开始时间: 2009年2月17日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
58
试验地点
11
主要终点
Summary of Visual Analog Scales (VAS) of Pain Intensity Change From Baseline by Treatment Group With Single Dose of Oxymorphone IR Tablet and Multiple Dose of Oxymorphone IR Tablet

研究概览

简要总结

When post-operative parenteral analgesia is discontinued, oral dosing with study medication may begin once the subject has developed a moderate level of pain as defined by a 100 mm VAS (pain intensity score greater than or equal to 40).

This post marketing study was required by the FDA. Endo Pharmaceuticals Inc. no longer promotes opioids and no longer markets Opana® ER.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
12 Years 至 17 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Male or female > 12 to 17 years of age, inclusive
  • Weigh at least 50 kg
  • Postoperative oral opioid analgesia required for at least 24 hours or 48 hours following postoperataive parenteral analgesia
  • Are expected to be hospitalized for the duration of the study

排除标准

  • Known allergy to, or a significant reaction to, oxymorphone or another opioid
  • Life expectancy of < 4 weeks
  • Positive pregnancy test at screening

研究组 & 干预措施

Oxymorphone IR

Experimental

Open-Label, 2 part ascending-dose multicenter study

干预措施: Oxymorphone IR (Drug)

结局指标

主要结局

Summary of Visual Analog Scales (VAS) of Pain Intensity Change From Baseline by Treatment Group With Single Dose of Oxymorphone IR Tablet and Multiple Dose of Oxymorphone IR Tablet

时间窗: Single Dose Timeframe: 15min, 30min, 1h, 2h, 3h, 4h, 6h or Rescue; Multiple Dose Timeframe: 15min, 30min, 1h, 2h, 3h, 4h, 6h, subsequent doses every 4-6 hours (Multiple Dose #1-11), and Early Termination

Change from Baseline in 100-mm Visual Analog Scales (VAS) in Multiple Dose of Oxymorphone IR Tablet

Subjects Taking Rescue Medication

时间窗: first dose through 48 hours after first dose

Percentages are based on the number of subjects in each treatment group.

次要结局

  • AUC(0-t) of Single Dose of Oxymorphone by Treatment Group(Baseline, 2h, 4h, 8h, 12h, 24h, 28h, 32h, 36h and 48h)
  • AUC(0-inf) of Single Dose of Oxymorphone by Treatment Group(Baseline, 2h, 4h, 8h, 12h, 24h, 28h, 32h, 36h and 48h)
  • Cmax of Single Dose of Oxymorphone by Treatment Group(Baseline, 2h, 4h, 8h, 12h, 24h, 28h, 32h, 36h and 48h)
  • Tmax of Single Dose of Oxymorphone by Treatment Group(Baseline, 2h, 4h, 8h, 12h, 24h, 28h, 32h, 36h and 48h)
  • Terminal Rate Constant of Single Dose of Oxymorphone by Treatment Group(Baseline, 2h, 4h, 8h, 12h, 24h, 28h, 32h, 36h and 48h)
  • Terminal Half-life of Single Dose of Oxymorphone by Treatment Group(Baseline, 2h, 4h, 8h, 12h, 24h, 28h, 32h, 36h and 48h)

研究者

发起方
Endo Pharmaceuticals
申办方类型
Industry
责任方
Sponsor

研究点 (11)

Loading locations...

相似试验